Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | Deucravacitinib - (IM011-127) | Ulcerative colitis (UC) | Phase 2 | Trial Discontinued | oral | Gastroenterology |
| Bristol-Myers Squibb Company | Sitravatinib and OPDIVO (nivolumab) | Urothelial Carcinoma (Bladder) | Phase 2 | Trial Completed | Intravenous | Oncology |
| Burning Rock Biotech Limited | Brigimadlin - (Brightline-2, China trial) | MDM2-amplified, TP53 wild-type solid tumors | Phase 2 | Ongoing | Oral | Oncology |
| Cabaletta Bio Inc. | Rese-cel (resecabtagene autoleucel (CABA-201) - (RESET-Myositis) | Active idiopathic inflammatory myopathy (IIM, or myositis) | BLA Filing | Data Released | Intravenous | Immunology |
| Cadrenal Therapeutics Inc. | Frunexian (EP-7041) | Factor XIa agent for acute anticoagulation | Phase 2 | Ongoing | Intravenous | Anticoagulant |
| Cadrenal Therapeutics Inc. | tecarfarin - (ARIES-HM3) | Thromboembolism and thrombosis | Phase 2 | Ongoing | oral | Anticoagulant |
| Cadrenal Therapeutics Inc. | Tecarfarin - (TECH-LVAD) | Left Ventricular Assist Devices (LVADs) patients with advanced heart failure | Phase 3 | Ongoing | Oral | Cardiology |
| Cadrenal Therapeutics Inc. | VLX-1005 | Heparin-Induced Thrombocytopenia (HIT) | Phase 3 | Trial Planned | Intravenous | Hematology |
